What Fresenius SE & Co. KGaA does.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Revenue and profit, by fiscal year.

More on FRE.DE.

• Fresenius SE & Co. KGaA summary
• Fresenius SE & Co. KGaA financial statements
• Fresenius SE & Co. KGaA key metrics
• Fresenius SE & Co. KGaA health scores
• Fresenius SE & Co. KGaA valuation
• Fresenius SE & Co. KGaA dividends
• Fresenius SE & Co. KGaA peers
• Fresenius SE & Co. KGaA annual reports

Figures from Fresenius SE & Co. KGaA's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.